Subscribe
shutterstock_1155148972_atmosphere1
Atmosphere1 / Shutterstock.com
26 October 2022GenericsStaff Writer

MSD hit with €39m fine over contraceptive generic delay

The probe in Spain centred on the delayed entry of generic versions of a branded contraceptive | The commission found evidence of “unjustified legal action”.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More on this story

Big Pharma
MSD prevails in diabetes drug dispute with Mylan
29 September 2022   MSD, known as Merck in the US and Canada, has won against a case concerning branded diabetes treatment Janumet XR at the US Court of Appeals for the Federal Circuit.
Americas
MSD makes $1.4bn bid on biopharma company
22 November 2022   Move could garner ‘milestone’ treatment for one of MSD’s portfolios | Activity comes after a Spanish watchdog fined the pharma firm $39 million.
Americas
MSD accuses university of patent contract breach
1 December 2022   Ex-partners collaborated on a clinical study for a cancer treatment | Pharma firm insists that it has exclusive licensing rights | MSD | John Hopkins.

More features

Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court
Cooley adds ex-Gowling partner